Skip to content

Research for the academic thoughts and clinical experience of professor Shen Ziyin for bronchial asthma

Research for the academic thoughts and clinical experience of professor Shen Ziyin for bronchial asthma

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021858
Enrollment
Unknown
Registered
2019-03-13
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchial asthma

Interventions

Experimental group:ICS/LABA+Bu-Shen-Yi-Qi Decoction

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Repeated attacks of wheezing, chest tightness, shortness of breath or cough, mostly due to exposure to allergens, physical and chemical sounds, scattered stimulation, viral infection of the upper respiratory tract, sports, etc.; (2) It can be heard in both lungs and wheeze mainly in the exhalation phase or diffuse, and extend in the exhalation phase; (3) The above symptoms and signs can be relieved by themselves or after treatment; (4) Wheezing, chest tightness and cough caused by other diseases were excluded; (5) Patients with relatively complete medical records should have at least the contents of symptoms, syndrome type/treatment, prescriptions, dosage, etc.

Exclusion criteria

Exclusion criteria: (1) Patients with bronchiectasis, active pulmonary tuberculosis, pulmonary infection, pulmonary interstitial fibrosis, pneumothorax, pleural effusion, pulmonary embolism, or neuromuscular diseases affecting respiratory motor function; (2) Patients who need long-term oral glucocorticoid or more than 3 kinds of asthma control drugs recommended by the long-term use guidelines; (3) Women who are pregnant or plan to become pregnant or lactating; (4) Have participated in the clinical trials of other drugs within 3 months; (5) Patients with severe cardiac, liver and renal function impairment (cardiac function level 3 ~ 4, ALT and/or AST exceeding 1.5 times of the normal upper limit, Cr exceeding the normal upper limit); (6) TCM identifies patients with Yin deficiency and fire flourishing syndrome.

Design outcomes

Primary

MeasureTime frame
ACT score;Acute exacerbation rate;

Secondary

MeasureTime frame
Quantitative score of asthma symptoms;lung function;The use of Reliever;Frequency of acute exacerbations;Peripheral blood inflammatory markers;Quality of life questionnaire;

Countries

China

Contacts

Public ContactDong Jingcheng

Huashan Hospital, Fudan University

jcdong2004@126.com+86 13601761761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026